Mortality in the survival with oral D-sotalol (SWORD) trial: Why did patients die?

American Journal of Cardiology

Volumn 81, Issue 7, 1998, Pages 869-876

  Pratt, Craig M ^a   Camm, A John ^b   Cooper, William ^b   Friedman, Peter L ^b   MacNeil, Daniel J ^b   Moulton, Kathleen M ^b   Pitt, Bertram ^b   Schwartz, Peter J ^b   Veltri, Enrico P ^b   Waldo, Albert L ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; SOTALOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; RISK; SEX DIFFERENCE; TORSADE DES POINTES;

EID: 0032053864     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00006-X     Document Type: Article

References (38)

1. 1. Ruberman W, Weinblatt E, Goldberg JD, Frank CS, Chaudhary BS, Shapiro S. Ventricular premature complexes and sudden death after myocardial infarction. Circulation 1981;64:297-305.
2. 2. Moss AJ, Davis HT, DeCamilla J, Bayer LW. Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation 1979;60:998-1003.
3. 3. Bigger JT, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM, and the Multicenter Post-Infarction Research Group. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250-258.
4. 4. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after myocardial infarction: The CAPS. Am J Cardiol 1988;61:501-509.
5. 5. Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982;65:457-464.
6. 6. Marcus FL, Cobb LA, Edwards JE, Kuller L, Moss AJ, Bigger T, Fleiss JL, Rolnitzky L, Serokman R, and the Multicenter Post Infarction Research Group. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after myocardial infarction. Am J Cardiol 1988;6:8-15.
7. 7. Greene HL, Richardson DW, Barker AH, Roden DM, Capone RJ, Echt DS, Friedman LM, Gillespie MJ, Hallstrom AP, Verter J, and the CAPS Investigators. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (The Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989;63:1-6.
8. 8. Pratt CM, Francis MF, Luck J, Wyndham C, Miller R, Quinones MA. Analysis of ambulatory electrocardiograms in 15 patients during spontaneous ventricular fibrillation with special reference to preceeding arrhythmic events. J Am Coll Cardiol 1983;2:789-797.
9. 9. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-159.
10. 10. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pitt B, Pratt CM, Rodda BE, Schwartz PJ, for the SWORD Investigators. The SWORD trial. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design and methods. Am J Cardiol 1995;75: 1023-1027.
11. 11. Johnston GD, Finch MB, McNeill JA, Shanks RG. A comparison of the cardiovascular effects of (+)-sotalol and (±)-sotalol following intravenous administration in normal volunteers. Br J Clin Pharmacol 1985;20:507-510.
12. 12. Lynch JJ, Coskey LA, Montgomery DG, Lucchesi BR. Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. Am Heart J 1985;109:949-958.
13. + channel blockade in the prevention of ventricular fibrillation due to acute ischemia and enhanced sympathetic activity. J Cardiovasc Pharmacol 1995;26:847-854.
14. 14. Kato R, Ikeda N, Yabek S, Ramaswamy K, Singh B. Electrophysiologic effects of the levo-and dextrorotatory isomers of sotalol in isolated muscle and their in vivo pharmacokinetics. J Am Coll Cardiol 1986;7:116-125.
15. 15. Gomoll AW, Bartek MJ. Comparative β-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. Eur J Pharmacol 1986;132:123-135.
16. 16. Yasuda SU, Barbey JT, Funck-Buntano C, Wellstein A, Woosley RL. d-Sotalol reduces heart rate in vivo through a β-adrenergic receptor-independent mechanism. Clin Pharmacol Ther 1993;53:436-442.
17. 17. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
18. 18. Priori SG, Diehl L, Schwartz PJ. Torsades de pointes. In: Podrid PJ, Kowey PR, ed. Cardiac Arrhythmia, Mechanisms, Diagnosis and Management. Baltimore, MD: Williams & Wilkins, 1995:951-963.
19. 19. Cox DR. Regression models and life-tables. J Roy Stat Soc 1972;34:187-202.
20. 20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. 21. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72:44A-50A.
22. 22. Investigators Brochure: d-Sotalol. Bristol-Myers Squibb. November 1, 1993.
23. 23. Schwartz PJ, Locati E. QT interval lengthening and cardiac arrhythmias. In: Singh BN, ed. Control of Cardiac Arrhythmias by Lengthening Repolarization. Mount Kisco, NY: Futura Publishing Co., 1988:129-152.
24. 24. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988;31:115-172.
25. 25. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
26. 26. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsades de pointes: the long-short initiating sequence and other clinical features. Am J Cardiol 1983;2:806-817.
27. 27. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B, Rosen KM. Torsades de pointes due to quinidine observations in 31 patients. Am Heart J 1984; 107:425-430.
28. 28. Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989; 118:433-440.
29. 29. Hallstrom A, Pratt CM, Greene HL, Huther M, Gottlieb S, DeMaria A, Young JB. The interrelationships between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial (The CAST). J Am Coll Cardiol 1995;25:1250-1257.
30. 30. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989; 80:1675-1680.
31. 31. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. An exploration of the precision of classifying sudden cardiac death: implications for the interpretation of clinical trials. Circulation 1996;93:519-524.
32. 32. Bigger JT. Why patients with congestive heart failure die: arrhythmias and sudden cardiac death. Circulation 1987;75:IV28-IV35.
33. 33. Zeische S, Rector TS, Cohn JN. Interobserver discordance in the classification of mechanisms of death in studies of heart failure. J Cardiac Failure 1995;1:127-132.
34. 34. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321: 406-612.
35. 35. The Cardiac Arrhythmia Suppression Trial II (CAST II) Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
36. 36. Echt DS, Leibson PR, Mitchell B, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781-788.
37. 37. Pratt CM, Moye LA. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. Am J Cardiol 1990;65:20B-29B.
38. 38. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;22:1142-1147.